NASDAQ:WVEWave Life Sciences Stock Price, Forecast & News

Wave Life Sciences' stock was trading at $8.12 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, WVE stock has increased by 17.9% and is now trading at $9.57. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Wave Life Sciences.

Wave Life Sciences is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Wave Life Sciences.

Wave Life Sciences Ltd (NASDAQ:WVE) released its quarterly earnings results on Monday, May, 11th. The company reported ($1.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.34) by $0.04. The firm had revenue of $4.16 million for the quarter, compared to analysts' expectations of $7.26 million. Wave Life Sciences had a negative return on equity of 219.06% and a negative net margin of 1,150.43%. View Wave Life Sciences' earnings history.

6 brokers have issued 1 year price objectives for Wave Life Sciences' shares. Their forecasts range from $10.00 to $65.00. On average, they expect Wave Life Sciences' stock price to reach $28.00 in the next year. This suggests a possible upside of 192.6% from the stock's current price. View analysts' price targets for Wave Life Sciences.

Headlines about WVE stock have been trending very negative on Wednesday, InfoTrie reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Wave Life Sciences earned a daily sentiment score of -3.1 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View the latest news aboutWave Life Sciences.

Wave Life Sciences saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 4,980,000 shares, an increase of 9.7% from the April 30th total of 4,540,000 shares. Based on an average daily trading volume, of 620,800 shares, the short-interest ratio is currently 8.0 days. Approximately 17.6% of the company's shares are sold short. View Wave Life Sciences' Current Options Chain.

Some companies that are related to Wave Life Sciences include Tricida (TCDA), Arvinas (ARVN), Karyopharm Therapeutics (KPTI), Kiniksa Pharmaceuticals (KNSA), Cytokinetics (CYTK), Supernus Pharmaceuticals (SUPN), Mersana Therapeutics (MRSN), Revance Therapeutics (RVNC), Phathom Pharmaceuticals (PHAT), I-Mab (ARQT), Esperion Therapeutics (ESPR), Aimmune Therapeutics (AIMT), Odonate Therapeutics (ODT), MacroGenics (MGNX) and Phibro Animal Health (PAHC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD), Crispr Therapeutics (CRSP), Exelixis (EXEL), Novavax (NVAX), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), Aduro BioTech (ADRO), Micron Technology (MU), AT&T (T) and TherapeuticsMD (TXMD).

Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE."

Wave Life Sciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (8.74%), Redmile Group LLC (8.39%), BlackRock Inc. (5.25%), Primecap Management Co. CA (3.56%), JPMorgan Chase & Co. (2.25%) and Morgan Stanley (1.96%). Company insiders that own Wave Life Sciences stock include Chandra Vargeese, Chris Francis, Gregory L Verdine, Keith Regnante, Michael A Panzara, Paul Bolno and Ra Capital Management, Llc. View institutional ownership trends for Wave Life Sciences.

WVE stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Wellington Management Group LLP, Primecap Management Co. CA, Burrage Capital Management LLC, Spark Investment Management LLC, Parametric Portfolio Associates LLC, BlackRock Inc., and WS Management Lllp. Company insiders that have sold Wave Life Sciences company stock in the last year include Chandra Vargeese, Gregory L Verdine, Michael A Panzara, and Paul Bolno. View insider buying and selling activity for Wave Life Sciences.

WVE stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, JPMorgan Chase & Co., Pictet Asset Management Ltd., Voloridge Investment Management LLC, Russell Investments Group Ltd., Nuveen Asset Management LLC, and Tekla Capital Management LLC. View insider buying and selling activity for Wave Life Sciences.

Shares of WVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of WVE stock can currently be purchased for approximately $9.57.

Wave Life Sciences has a market capitalization of $333.93 million and generates $15.98 million in revenue each year. The company earns $-193,640,000.00 in net income (profit) each year or ($5.72) on an earnings per share basis. Wave Life Sciences employs 250 workers across the globe.

The official website for Wave Life Sciences is www.wavelifesciences.com.

Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The company can be reached via phone at 65-6236-3388 or via email at [email protected]